Treatment with single doses of antibiotics of uncomplicated urinary tract infections in women is a well-established therapeutic regimen (1, 4, 12, 15, 20) . Therapeutic failures following a single-dose treatment appear to predict complicating factors such as silent pyelonephritis (14), morphologic alterations, dynamic disturbances, or microbial resistance to antibiotics (6, 8, 11, 13) .
Treatment with single doses of antibiotics of uncomplicated urinary tract infections in women is a well-established therapeutic regimen (1, 4, 12, 15, 20) . Therapeutic failures following a single-dose treatment appear to predict complicating factors such as silent pyelonephritis (14) , morphologic alterations, dynamic disturbances, or microbial resistance to antibiotics (6, 8, 11, 13) .
Ciprofloxacin, a new'quinolone drug which can be administered both orally and intravenously, has good antimicrobial activity against microorganisms frequently found in urinary tract infections. The aim of the present study was to evaluate the efficacy of a single dose of ciprofloxacin in the treatment of uncomplicated'urinary tract infection. In addition, two oral doses, 250 and 100 mg, were compared to estimate clinical and bacteriological efficacy at the lower-dosage range.
Women 16 years or older attending our outpatient clinic were enrolled in the study if they presented with acute dysuria and frequent micturition of <72 h in' duration. Admission criteria included bacteriuria (>102 CFPU/ml) and pyuria (>10 leukocytes per mm3). Exclusion criteria were pregnancy, fever of >38°C, serum creatinine of >115 pumol/liter, and a history of antecedent complicated urinary tract infection (e.g., due to obstruction in the u4nary tract).
Uncomplicated recurrent urinary tract infections did not lead to exclusion. A total blood count, erythrocyte sedimentation rate, serum creatinine, alkaline phosphatase, and glutamate pyruvate transaminase were determined at presentation.
Midstream urine was collected after individual instruction of the patient and was cultivated quantitatively on human blood and MacConkey agar plates. Uropathogenic microorganisms were differentiated according to standard methods, and Staphylococcus saprophyticus was identified by the novobiocin method (5) . A routine sensitivity test by photometric measurement of the optical density (MS-2 automated antimicrobial susceptibility testing system; Abbott Laboratories, Chicago, Ill.), as well as determinations of MICs by a micromethod (16) in Mueller-Hinton broth and a disk test on Mueller-Hinton agar for ciprofloxacin, was performed for all isolates (2) . Patients received either 100 or 250 mg of ciprofloxacin orally at presentation, before any laJoratory values were available.
A total of 40 women with a median age of 25.0 years (range, 18 to 61 years) entered the study, 2 of whom had to be excluded because initial culture-s were inconclusive * Corresponding author.
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(mixed flora). Thirty-eight women completed the study; 19 received 100 mg and 19 received 250 mg of ciprofloxacin orally as a single dose. Laboratory values at presentation revealed an elevated leukocyte count (>10,000/mm3) in four cases and a leukocytosis with accelerated erythrocyte sedimentation rate (>20 mm/h).in one case in each treatment group. All other laboratory values, including serum creatinine, were normal in all patients.
In both treatment groups, the predominant microorganism isolated from urine was Escherichia coli, whereas the other causative microorganisms (S. saprophyticus, Proteus mirabilis, Enterobacter cloacae) were comparatively rare. In one case, both P. mirabilis and S. saprophyticus were isolated (Table 1) .
At the first follow-up 4 to 5 days after the treatment with ciprofloxacin, 5 of 38 (13%) patients had a clinical and bacteriological failure, defined as continuing symptoms, pyuria (>10 leukocytes per mm3), and the repeated isolation of the same causative microorganisms at concentrations exceeding 102 CFU/ml. There were two clinical and bacteriological failures (E. coli, S. saprophyticus) in the 250-mg groups and three failures in the 100-mg group (E. coli twice, S. saprophyticus once; Table 1 ). In the patient who initially presented with P. mirabilis and S. saprophyticus in concentrations of >105 CFU/ml, S. saprophyticus persisted, whereas P. mirabilis was eradicated after 5 days. The five patients with therapeutic failure were subsequently treated with 'an alternative antibiotic for 2 weeks according to sensitivity results.
At a 4-week follow-up there were two cases with reinfection in the 250-mg group (E. coli). In the 100-mg group, one reinfection with Citrobacter sp. and one rela,pse (E. coli) were documented. Reinfection was defined as clinical and laboratory evidence of a new infection after a normal first follow-up, whereas relapse was defined as isolation of the original pathogen after a sterile first urine specimen. Identity of microorganisms was assumed when pre-and posttreatment cultures exhibited the same biotype in the API 20E system and the antibiogram.
The MICs of ciprofloxacin for all initial isolates were c2 mg/liter'(range, 0.0037 to 2.0 mg/liter). All Four strains of S. saprophyticus and four strains of E. coli (two each isolated from patients with therapeutic failures and two each from patients with successful therapy) were examined in vitro to evaluate the rate of killing by high-dose (100-mg/liter) ciprofloxacin. Killing curves were performed in Mueller-Hinton broth supplemented with magnesium and calcium-. The concentration of ciprofloxacin in broth was 100 mg/liter. A final inoculum of about 106 CFU/ml was incubated at 35°C, and quantitative subcultures were repeatedly performed for 24 h. Colony counts were obtained by filtration of 100 ,ul of the inoculated broth through Micropore membranes (type SM 13806; Sartorius, Gottingen, Federal Republic of Germany). The filters were rinsed with sterile physiological saline to eliminate antibiotic residues and then incubated on Mueller-Hinton agar at 35TC. After 24 h, the number of colonies on the filter was counted at a 16-fold magnification (sensitivity limit, 101 CFU/ml). No difference was seen between strains which were eradicated by singledose therapy and those which persisted, but there was a striking difference between the gram-positive and the gramnegative microorganisms. While colony counts of E. coli decreased by at least 3 log CFU/ml within <1 h of exposure to ciprofloxacin, the average time to reduce S. saprophyticus by 3 log CFU/ml was 6 h (Fig. 1) .
Clinical and microbiological success rates were 89 and 84% after single doses of 250 and 100 mg of ciprofoxacin, respectively. There was no significant difference in success rates between the two dosages examined in this study. Recently, published studies revealed similar treatment results for the effectiveness of single-dose treatment with an average success rate of 85% (range, 65 to 100%) for trimethoprim, trimethoprim-sulfamethoxazole, or amoxycillin (3, 7, 10, 17, 19, 20) .
We found no concomitant complicating factors that could explain the treatment failures in our patients, although invasive tests were not performed. In particular, previous episodes of urinary tract infections had been successfully treated by single doses of antibiotics in one case of persistent S. saprophyticus infection. Treatment failures were due to neither resistance nor development of resistance to ciprofloxacin in any of our cases.
That 2 of 4 infections caused by S. saprophyticus were not cured, while only 3 of 35 infections caused by gram-negative organisms persisted, caused considerable concern. Although this difference did not reach statistical significance because of the small number of cases caused by S. saprophyticus, we sought to determine whether there was a systematic difference between the killing rates for S. saprophyticus and gram-negative organisms by ciprofloxacin. Our in vitro results illustrate that E. coli was rapidly killed by the drug, whereas S. saprophyticus was killed at a significantly slower rate. The concentration of ciprofloxacin examined in these experiments, which exceeds the MIC for our tested microorganisms approximately 100-fold, can be expected to be maximally bactericidal as shown by previous in vitro studies (18) . Since concentrations of ciprofloxacin similar to those used in our in vitro study are found in urine (9, 15) , these results suggest a clinically relevant reduction of the bactericidal activity of ciprofloxacin against S. saprophyticus compared with E. coli. However, the activity of ciprofloxacin does not appear to be the sole important factor for cure, since not all infections caused by S. saprophyticus failed to be eradicated and some infections caused by E. coli were not cured by a single dose of ciprofloxacin.
Our study shows a high effectiveness of single-dose administration of ciprofloxacin in the treatment of uncomplicated urinary tract infections in women, with the possible exception of infections caused by S. saprophyticus. Ciprofloxacin deserves special consideration in cases in which established regimens (amoxycillin, co-trimoxazole) cannot be administered because of a history of allergy or drug resistance.
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